Analyzing blood nucleosomes in patients with non-Hodgkin lymphoma during treatment
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NA · Gustave Roussy, Cancer Campus, Grand Paris · NCT06813573
This study is testing if measuring certain blood markers in patients with non-Hodgkin lymphoma during their first treatment can help doctors see how well the treatment is working.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Villejuif) |
| Trial ID | NCT06813573 on ClinicalTrials.gov |
What this trial studies
This study aims to prospectively monitor the levels of circulating nucleosomes in patients diagnosed with non-Hodgkin lymphoma, specifically those receiving first-line treatment with the RCHOP 21 regimen. By analyzing blood samples, the study seeks to determine if there is a correlation between nucleosome levels and clinical response to treatment. This approach may provide insights into the effectiveness of the therapy and help tailor future treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals with a histologically confirmed diagnosis of diffuse large B-cell lymphoma or follicular lymphoma who are starting first-line treatment with the RCHOP 21 regimen.
Not a fit: Patients with a history of previous lymphoma treatment or those receiving a chemotherapy regimen other than RCHOP21 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring of treatment response in non-Hodgkin lymphoma patients.
How similar studies have performed: While the specific approach of monitoring circulating nucleosomes is novel, similar studies have shown promise in correlating biomarkers with treatment responses in various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen * Agreement to participate after receiving oral and written information on the study Exclusion Criteria: * History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma) * Treatment with a chemotherapy regimen different from RCHOP21
Where this trial is running
Villejuif
- Gustave Roussy — Villejuif, France (RECRUITING)
Study contacts
- Study coordinator: David GHEZ
- Email: david.ghez@gustaveroussy.fr
- Phone: +33 1 42 11 42 40
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Follicular Lymphoma, Diffuse Large B-Cell Lymphoma